Abstract
Allogeneic peripheral blood progenitor cell (PBPC) transplants are an alternative to BMT, although G-CSF mobilization dose, timing of pheresis and risk of GVHD are not well defined. We compared harvest characteristics, donor and recipient outcomes and costs of two PBPC transplant strategies with historical controls who received BMT. Twenty donors mobilized with four daily s.c. G-CSF doses (5 μg/kg/day) (group 1) and 20 mobilized with 10 μg/kg/day G-CSF (group 2) were compared with 20 BM controls (group 3). G-CSF and phereses were well tolerated. Four of 40 PBPC donors required femoral catheter placement. At least 2.5 × 106 CD34+/kg recipient weight were collected with two phereses in 19/20 donors (group 1) and 18/20 donors (group 2). Time to neutrophil (18 vs 20 vs 22 days, P = 0.02) and platelet (21 vs 24 vs 27 days, P = 0.005) engraftment was shorter in the PBPC groups (group 2 vs group 1 vs group 3) but secondary engraftment outcomes were not different. The incidence of grade 2–4 aGVHD was higher in the low-dose G-CSF group (group 1) but there was no difference in cGVHD, 100-day or 1-year survival. The mean PBPC transplant cost (group 1) at first hospital discharge was less than BM (group 3) ($34 643 vs $37 354) but the mean overall cost for both groups was similar at 100 days ($46 334 vs $46 083). Allogeneic PBPC transplant with short course, low-dose G-CSF mobilization is safe, feasible and cost equivalent to allogeneic BMT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Couban, S., Dranitsaris, G., Andreou, P. et al. Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Bone Marrow Transplant 22, 1199–1205 (1998). https://doi.org/10.1038/sj.bmt.1701504
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701504
Keywords
This article is cited by
-
Differences between graft product and donor side effects following bone marrow or stem cell donation
Bone Marrow Transplantation (2003)
-
Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study
Bone Marrow Transplantation (2003)
-
Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation
Bone Marrow Transplantation (2000)
-
Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children
Bone Marrow Transplantation (2000)
-
A randomised study of allogeneic transplantation with stem cells from blood or bone marrow
Bone Marrow Transplantation (2000)